JP2013536853A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013536853A5 JP2013536853A5 JP2013527248A JP2013527248A JP2013536853A5 JP 2013536853 A5 JP2013536853 A5 JP 2013536853A5 JP 2013527248 A JP2013527248 A JP 2013527248A JP 2013527248 A JP2013527248 A JP 2013527248A JP 2013536853 A5 JP2013536853 A5 JP 2013536853A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutical composition
- composition according
- salt
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 21
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 201000010099 disease Diseases 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 6
- 102000042838 JAK family Human genes 0.000 claims 5
- 108091082332 JAK family Proteins 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 230000002062 proliferating effect Effects 0.000 claims 4
- DCRWIATZWHLIPN-QGZVFWFLSA-N (r)-(4-fluorophenyl)-[4-[(5-methyl-1h-pyrazol-3-yl)amino]quinazolin-2-yl]methanol Chemical compound N1C(C)=CC(NC=2C3=CC=CC=C3N=C(N=2)[C@H](O)C=2C=CC(F)=CC=2)=N1 DCRWIATZWHLIPN-QGZVFWFLSA-N 0.000 claims 3
- 230000000155 isotopic effect Effects 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003054 catalyst Substances 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- WDYGPMAMBXJESZ-SFHVURJKSA-N (2s)-1,1-bis(4-methoxyphenyl)-3-methylbutane-1,2-diamine Chemical compound C1=CC(OC)=CC=C1C(N)([C@@H](N)C(C)C)C1=CC=C(OC)C=C1 WDYGPMAMBXJESZ-SFHVURJKSA-N 0.000 claims 1
- DCRWIATZWHLIPN-UHFFFAOYSA-N (4-fluorophenyl)-[4-[(5-methyl-1h-pyrazol-3-yl)amino]quinazolin-2-yl]methanol Chemical compound N1C(C)=CC(NC=2C3=CC=CC=C3N=C(N=2)C(O)C=2C=CC(F)=CC=2)=N1 DCRWIATZWHLIPN-UHFFFAOYSA-N 0.000 claims 1
- OGWVFYOLYMSTEP-UHFFFAOYSA-N (4-fluorophenyl)-[4-[(5-methyl-1h-pyrazol-3-yl)amino]quinazolin-2-yl]methanone Chemical compound N1C(C)=CC(NC=2C3=CC=CC=C3N=C(N=2)C(=O)C=2C=CC(F)=CC=2)=N1 OGWVFYOLYMSTEP-UHFFFAOYSA-N 0.000 claims 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical group N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000003821 enantio-separation Methods 0.000 claims 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical group CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000006207 intravenous dosage form Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37928610P | 2010-09-01 | 2010-09-01 | |
| US37928010P | 2010-09-01 | 2010-09-01 | |
| US61/379,286 | 2010-09-01 | ||
| US61/379,280 | 2010-09-01 | ||
| PCT/US2011/049895 WO2012030913A1 (en) | 2010-09-01 | 2011-08-31 | An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013536853A JP2013536853A (ja) | 2013-09-26 |
| JP2013536853A5 true JP2013536853A5 (OSRAM) | 2014-09-25 |
| JP5932794B2 JP5932794B2 (ja) | 2016-06-08 |
Family
ID=45698050
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013527248A Expired - Fee Related JP5932794B2 (ja) | 2010-09-01 | 2011-08-31 | 光学活性のあるピラゾリルアミノキナゾリン及びその医薬組成物及び使用方法 |
| JP2013527249A Expired - Fee Related JP5933554B2 (ja) | 2010-09-01 | 2011-08-31 | 光学活性のあるピラゾリルアミノキナゾリン及びその医薬組成物及び使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013527249A Expired - Fee Related JP5933554B2 (ja) | 2010-09-01 | 2011-08-31 | 光学活性のあるピラゾリルアミノキナゾリン及びその医薬組成物及び使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US8912324B2 (OSRAM) |
| EP (2) | EP2611796B1 (OSRAM) |
| JP (2) | JP5932794B2 (OSRAM) |
| AR (2) | AR082875A1 (OSRAM) |
| AU (2) | AU2011296078B2 (OSRAM) |
| CA (2) | CA2809994A1 (OSRAM) |
| ES (2) | ES2581840T3 (OSRAM) |
| TW (2) | TW201305143A (OSRAM) |
| WO (2) | WO2012030913A1 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2581840T3 (es) * | 2010-09-01 | 2016-09-07 | Ambit Biosciences Corporation | Pirazolilaminoquinazolina ópticamente activa y composiciones farmacéuticas y métodos de uso de la misma |
| EP2611792B1 (en) * | 2010-09-01 | 2017-02-01 | Ambit Biosciences Corporation | Hydrobromide salts of a pyrazolylaminoquinazoline |
| US9611253B2 (en) | 2012-02-29 | 2017-04-04 | Ambit Biosciences Corporation | Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith |
| DK3179992T3 (da) | 2014-08-11 | 2022-07-11 | Acerta Pharma Bv | Terapeutisk kombination af en btk-inhibitor, en pd-1-inhibitor og/eller en pd-l1-inhibitor |
| DK3179991T3 (da) | 2014-08-11 | 2021-12-06 | Acerta Pharma Bv | Terapeutiske kombinationer af en btk-inhibitor og en bcl-2-inhibitor |
| WO2016024232A1 (en) | 2014-08-11 | 2016-02-18 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor |
| WO2024032527A1 (zh) * | 2022-08-08 | 2024-02-15 | 石药集团中奇制药技术（石家庄）有限公司 | 一种含有三环杂芳基的化合物的用途 |
| WO2024201533A1 (en) * | 2023-03-31 | 2024-10-03 | Sava Healthcare Limited | A parenteral composition of cinnamic acid |
| CN118239990B (zh) * | 2024-05-28 | 2025-03-14 | 北京元延医药科技股份有限公司 | 不对称氢化催化合成药物的稀有贵金属和手性膦的配合物 |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
| KR890002631B1 (ko) | 1984-10-04 | 1989-07-21 | 몬산토 캄파니 | 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물 |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
| IT1246382B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6274552B1 (en) | 1993-03-18 | 2001-08-14 | Cytimmune Sciences, Inc. | Composition and method for delivery of biologically-active factors |
| US5985307A (en) | 1993-04-14 | 1999-11-16 | Emory University | Device and method for non-occlusive localized drug delivery |
| US5523092A (en) | 1993-04-14 | 1996-06-04 | Emory University | Device for local drug delivery and methods for using the same |
| US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6004534A (en) | 1993-07-23 | 1999-12-21 | Massachusetts Institute Of Technology | Targeted polymerized liposomes for improved drug delivery |
| US5958458A (en) | 1994-06-15 | 1999-09-28 | Dumex-Alpharma A/S | Pharmaceutical multiple unit particulate formulation in the form of coated cores |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5759542A (en) | 1994-08-05 | 1998-06-02 | New England Deaconess Hospital Corporation | Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases |
| US5660854A (en) | 1994-11-28 | 1997-08-26 | Haynes; Duncan H | Drug releasing surgical implant or dressing material |
| US6316652B1 (en) | 1995-06-06 | 2001-11-13 | Kosta Steliou | Drug mitochondrial targeting agents |
| US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
| WO1997001331A2 (en) | 1995-06-27 | 1997-01-16 | Takeda Chemical Industries, Ltd. | Method of producing sustained-release preparation |
| TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
| JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
| US6039975A (en) | 1995-10-17 | 2000-03-21 | Hoffman-La Roche Inc. | Colon targeted delivery system |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| TW345603B (en) | 1996-05-29 | 1998-11-21 | Gmundner Fertigteile Gmbh | A noise control device for tracks |
| US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
| EP1007012A4 (en) | 1996-10-01 | 2006-01-18 | Cima Labs Inc | TASTE-MASKED MICRO-CAPSULE COMPOSITION AND MANUFACTURING PROCESS |
| US6375987B1 (en) | 1996-10-01 | 2002-04-23 | Gattefossé, S.A. | Process for the manufacture of pharmaceutical composition with modified release of active principle comprising the matrix |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| ES2221019T3 (es) | 1996-10-31 | 2004-12-16 | Takeda Chemical Industries, Ltd. | Preparacion de liberacion mantenida. |
| US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
| DE19648576C2 (de) | 1996-11-23 | 1999-08-12 | Lohmann Therapie Syst Lts | Lutschtablette zur modifizierten Freisetzung von Wirkstoffen im Gastrointestinaltrakt |
| DE69719367T2 (de) | 1996-12-20 | 2003-10-16 | Takeda Chemical Industries, Ltd. | Verfahren zur herstellung einer zusammensetzung mit verzoegerter abgabe |
| US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
| US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
| US6350458B1 (en) | 1998-02-10 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Mixed micellar drug deliver system and method of preparation |
| US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| US6048736A (en) | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
| KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
| US7169410B1 (en) | 1998-05-19 | 2007-01-30 | Sdg, Inc. | Targeted liposomal drug delivery system |
| KR20070051953A (ko) | 1998-11-02 | 2007-05-18 | 엘란 코포레이션, 피엘씨 | 다입자 변형 방출 조성물 |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
| US6623756B1 (en) | 2000-04-27 | 2003-09-23 | Noveon Ip Holdings Corp. | Directly compressed solid dosage articles |
| AP2001002264A0 (en) | 2000-08-30 | 2001-09-30 | Pfizer Prod Inc | Sustained release formulations for growth hormone secretagogues. |
| AP2003002825A0 (en) | 2000-12-21 | 2003-09-30 | Vertex Pharma | Pyrazole compounds useful as protein kinase inhibitors |
| DE20220604U1 (de) | 2001-07-27 | 2004-02-26 | Yamanouchi Pharmaceutical Co., Ltd. | Zusammensetzung, enthaltend feine Partikel zur Langzeitfreisetzung für schnell in der Mundhöhle zerfallende Tabletten |
| CA2461682A1 (en) | 2001-09-28 | 2003-04-03 | Mcneil-Ppc, Inc. | Composite dosage forms |
| EP1355633B1 (en) | 2001-12-19 | 2005-01-19 | AstraZeneca AB | NEW FILM COATING containing an ethyl acrylate/methyl methacrylate copolymer and polyvinyl acetate |
| AR038117A1 (es) * | 2002-01-14 | 2004-12-29 | Upjohn Co | Agentes antivirales derivados de la 4- oxo-4,7 -dihidrofuro [2,3-b]piridin-5-carboxamida |
| US7112435B1 (en) | 2002-08-07 | 2006-09-26 | Ambit Biosciences Corporation | Uncoupling of DNA insert propagation and expression of protein for phage display |
| US6958161B2 (en) | 2002-04-12 | 2005-10-25 | F H Faulding & Co Limited | Modified release coated drug preparation |
| GB0211019D0 (en) * | 2002-05-14 | 2002-06-26 | Syngenta Ltd | Novel compounds |
| KR20050084292A (ko) * | 2002-12-13 | 2005-08-26 | 뉴로젠 코포레이션 | 캅사이신 수용체 조절체로서 2-치환된 퀴나졸린-4-일아민동족체 |
| US7485322B2 (en) | 2002-12-24 | 2009-02-03 | Lek Pharmaceuticals D.D. | Modified release pharmaceutical composition |
| CA2598383C (en) | 2005-02-18 | 2013-11-26 | The Hong Kong Polytechnic University | Method for asymmetric hydrosilylation of ketones |
| US20080280855A1 (en) * | 2005-06-22 | 2008-11-13 | Nycomed Gmbh | Process For the Production of Intermediates For the Preparation of Tricyclic Benzimidazoles |
| US7427414B2 (en) | 2006-01-18 | 2008-09-23 | Astron Research Limited | Modified release oral dosage form using co-polymer of polyvinyl acetate |
| EP2044219B1 (en) | 2006-06-30 | 2013-05-22 | DiscoveRx Corporation | Detectable nucleic acid tag |
| WO2008077560A1 (en) * | 2006-12-22 | 2008-07-03 | Lonza Ag | Process for the preparation of optically active 2-amino-1-phenylethanols |
| BRPI0808772A2 (pt) * | 2007-03-14 | 2014-08-12 | Exelixis Inc | Inibidores da via de hedgehog |
| MX2010002336A (es) * | 2007-08-28 | 2010-03-25 | Irm Llc | Derivados de 2-bifenil-amino-4-amino-pirimidina como inhibidores de cinasa. |
| JP2011513295A (ja) * | 2008-02-29 | 2011-04-28 | ファイザー・インク | インダゾール誘導体 |
| AP3272A (en) * | 2008-09-22 | 2015-05-31 | Cayman Chem Co | Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prosaglandin D2 mediated diseases |
| PL2401267T3 (pl) | 2009-02-27 | 2014-06-30 | Ambit Biosciences Corp | Pochodne chinazoliny modulujące kinazę JAK i ich zastosowanie w metodach |
| ES2581840T3 (es) * | 2010-09-01 | 2016-09-07 | Ambit Biosciences Corporation | Pirazolilaminoquinazolina ópticamente activa y composiciones farmacéuticas y métodos de uso de la misma |
-
2011
- 2011-08-31 ES ES11758009.2T patent/ES2581840T3/es active Active
- 2011-08-31 JP JP2013527248A patent/JP5932794B2/ja not_active Expired - Fee Related
- 2011-08-31 AU AU2011296078A patent/AU2011296078B2/en not_active Ceased
- 2011-08-31 US US13/222,963 patent/US8912324B2/en not_active Expired - Fee Related
- 2011-08-31 US US13/223,099 patent/US8703943B2/en not_active Expired - Fee Related
- 2011-08-31 JP JP2013527249A patent/JP5933554B2/ja not_active Expired - Fee Related
- 2011-08-31 WO PCT/US2011/049895 patent/WO2012030913A1/en not_active Ceased
- 2011-08-31 ES ES11758010.0T patent/ES2579942T3/es active Active
- 2011-08-31 EP EP11758010.0A patent/EP2611796B1/en not_active Not-in-force
- 2011-08-31 CA CA2809994A patent/CA2809994A1/en not_active Abandoned
- 2011-08-31 EP EP11758009.2A patent/EP2611795B1/en not_active Not-in-force
- 2011-08-31 CA CA2809993A patent/CA2809993A1/en not_active Abandoned
- 2011-08-31 WO PCT/US2011/049902 patent/WO2012030917A1/en not_active Ceased
- 2011-08-31 AU AU2011296074A patent/AU2011296074B2/en not_active Ceased
- 2011-09-01 TW TW100131607A patent/TW201305143A/zh unknown
- 2011-09-01 AR ARP110103206A patent/AR082875A1/es unknown
- 2011-09-01 AR ARP110103205A patent/AR082874A1/es unknown
- 2011-09-01 TW TW100131608A patent/TW201302732A/zh unknown
-
2014
- 2014-03-11 US US14/204,884 patent/US8952020B2/en not_active Expired - Fee Related
- 2014-11-18 US US14/546,938 patent/US9295672B2/en not_active Expired - Fee Related
-
2015
- 2015-01-12 US US14/595,033 patent/US20150353528A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013536853A5 (OSRAM) | ||
| JP2013536854A5 (OSRAM) | ||
| PH12014502531B1 (en) | Benzamine derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 | |
| PH12018550049A1 (en) | Protein kinase inhibitor, preparation method and medical use thereof | |
| JP2008539268A5 (OSRAM) | ||
| BR112012033715A2 (pt) | inibidores de quinase de regulação de sinal de apoptose. | |
| JP2014505008A5 (OSRAM) | ||
| WO2015123437A1 (en) | Cyclopropylamines as lsd1 inhibitors | |
| MX2009010951A (es) | Derivados de 3-amino-pirrolo[3,4-c]pirazol-5(1h,4h,6h)-carbaldehid o como inhibidores de proteina quinasa c. | |
| EA200800881A1 (ru) | Лекарственная форма пирфенидона в виде капсул с фармацевтически приемлемыми эксципиентами | |
| WO2020143762A1 (en) | Ketamine pamoate and use thereof | |
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| JP2009506014A5 (OSRAM) | ||
| EA201171087A1 (ru) | СПОСОБЫ ВВЕДЕНИЯ (4aR,10aR)-1-н-ПРОПИЛ-1,2,3,4,4a,5,10,10a-ОКТАГИДРОБЕНЗО[g]ХИНОЛИН-6,7-ДИОЛА И РОДСТВЕННЫХ СОЕДИНЕНИЙ ЧЕРЕЗ СЛИЗИСТУЮ ОБОЛОЧКУ ПОЛОСТИ РТА, СЛИЗИСТУЮ ОБОЛОЧКУ НОСА ИЛИ КОЖУ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ | |
| JP2020536893A5 (OSRAM) | ||
| MX2011010732A (es) | Pirimidinas sustituidas por imidazol utiles en el tratamiento de trastornos relacionados con glucogeno sintasa cinasa 3 como la enfermedad de alzheimer. | |
| JP2023506787A (ja) | Ｐａｒｐ阻害薬と組み合わせたａｔｒ阻害薬の使用 | |
| JP2010515682A5 (OSRAM) | ||
| JP2018531288A6 (ja) | ピリミジン組成物、超高純度組成物およびその塩、それを作成する方法、ならびにヒスタミンｈ４受容体（ｈ４）によって媒介される疾患および状態を治療するためにそれを用いる方法 | |
| JP2018531288A (ja) | ピリミジン組成物、超高純度組成物およびその塩、それを作成する方法、ならびにヒスタミンｈ４受容体（ｈ４）によって媒介される疾患および状態を治療するためにそれを用いる方法 | |
| AU2015336458A1 (en) | KCNQ2-5 channel activator | |
| Mu et al. | Discovery of sertraline and its derivatives able to combat drug-resistant gastric cancer cell via inducing apoptosis | |
| JP2015519347A5 (OSRAM) | ||
| JP2008538582A (ja) | 精神病性障害の治療または予防のための新規の治療的組み合わせ | |
| CN101022806A (zh) | （4－烷基哌嗪基）（苯基）甲酮在治疗阿尔茨海默病中的应用 |